NYSE:NUVBPharmaceuticals
Nuvation Bio (NUVB) Is Up 8.6% After Advancing Safusidenib Into Phase 3 Brain Cancer Trial
Nuvation Bio recently finalized a protocol amendment that expands its global SIGMA study of safusidenib into a Phase 3 trial, broadening eligibility to include patients with high‑risk grades 2 and 3 and grade 4 IDH1‑mutant astrocytoma after standard‑of‑care treatment.
This shift into a registrational Phase 3 setting materially advances safusidenib within Nuvation Bio’s pipeline, potentially reshaping the company’s role in treating aggressive IDH1‑mutant brain tumors.
Next, we’ll examine how...